Pathogenesis of amyotrophic lateral sclerosis

Biomedical Reviews

Volumn 22, Issue , 2011, Pages 7-14

  Kuźma Kozakiewicz, Magdalena ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Apoptosis; Axonal transport; Glial cells; Glutamate excitoxicity; Mitochondrial dysfunction; Oxidative stress; Superoxide dismutase

Indexed keywords

AMPA RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; COPPER ZINC SUPEROXIDE DISMUTASE; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; REACTIVE OXYGEN METABOLITE; RILUZOLE; RNA; TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CELL FUNCTION; CYTOSKELETON; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME INHIBITION; EXCITOTOXICITY; GLIA CELL; HUMAN; MOLECULAR MECHANICS; NERVE FIBER TRANSPORT; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; REVIEW; RNA PROCESSING;

EID: 84864000409     PISSN: 1310392X     EISSN: None     Source Type: Journal    
DOI: 10.14748/bmr.v22.31     Document Type: Review

References (61)

1. Kuźma-Kozakiewicz M, Kwieciński H. New therapeutic targets for amyotrophic lateral sclerosis (ALS). Exp Opinion Therap Targ 2011; 15:127-143.
2. Andersen P. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Current Neurol Neurosc Rep 2006; 6:37-46.
3. Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Gen 2010; 19:R46-R64.
4. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 364:362.
5. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264:1772-1775
6. Reaume AG, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996; 13:43-7.
7. Bruijn LI, Cleveland DW. Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease. Neuropathol Appl Neurobiol 1996; 22:373-387.
8. Bruijn LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998; 281:1851-1854.
9. Xu Z. Mechanism and treatment of motoneuron degeneration in ALS: what have SOD1 mutants told us? Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1:225-234.
10. Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 2006; 1762:1051-1067.
11. Shibata N, Nagai R, Miyata S, et al. Nonoxidative protein glycation is implicated in familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Acta Neuropathol 2000; 100:275-84.
12. Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995; 4:209-216.
13. Cho Y, Ueda T, Mori A, Shimizu H, Yozu R. Neuroprotective effects of N-methyl-D-aspartate receptor antagonist on aspartate induced neurotoxicity in the spinal cord in vivo. Jpn J Thorac Cardiovasc Surg 2003; 51(10):500-5.
14. Blaabjerg M, Fang L, Zimmer J, Baskys A. Neuroprotection against NMDA excitotoxicity by group I metabotropic glutamate receptors is associated with reduction of NMDA stimulated currents. Exp Neurol 2003; 183:573-580.
15. Trotti D, Danbolt NC, Volterra A. Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol Sci 1998; 19:328-334.
16. Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20:589-602.
17. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38:73-84.
18. Distad BJ, Meekins GD, Liou LL, Weiss MD, Carter GT, Miller RG. Drug therapy in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am 2008; 19:633-651.
19. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007; 1:CD001447
20. Kuner R., Groom A.J., Bresink I, et al. Late-onset motor neuron disease caused by a functionally modified AMPA receptor subunit. Proc Nat Acd Sci USA 2005; 102:5826-5831.
21. Hollmann M., Hartley M., Heinemann S. Ca2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 1991; 252:851-853.
22. Spalloni A, Pascucci T, Albo F, et al. Altered vulnerabil ity to kainate excitotoxicity of transgenic-Cu/Zn SOD1 neurones. Neuroreport 2004; 15:2477-2480.
23. Rembach A, Turner BJ, Bruce S, et al. Antisense peptide nucleic acid targeting GluR3 delays disease onset and progression in the SOD1 G93A mouse model of familial ALS. J Neurosci Res 2004; 77:573-582.
24. Georgiev DD, Hideo Taniura H, Yuki Kambe Y, Yoneda Y. Crosstalk between brain-derived neurotrophic factor and N-methyl-D-aspartate receptor signaling in neurons. Biomed Rev 2008; 19: 17-27.
25. Chaldakov GN. One more view of neurotrophin-neurotransmitter signaling inneurons: BDNF-AMPAR crosstalk [Editorial]. Biomed Rev 2008; 19: 29-32.
26. Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion 2005; 5:77-87.
27. Vielhaber S, Kunz D, Winkler K, et al. Mitochondrial DANN abnormalities in skeletal muscles of patients with amyotrophic lateral sclerosis. Brain 2000; 123:1339-1348.
28. Borthwick GM, Johnson MA, Ince PG, et al. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999; 46: 787-790.
29. Xu Z, Jung C, Higgins C, et al. Mitochondrial degeneration in amyotrophic lateral sclerosis. J Bioenerg Biomembr 2004; 36:395-399.
30. Wood JD, Beaujeux TP, Shaw PJ. Protein aggregation in motor neuron disorders. Neuropath Appl Neurobiol 2003; 29:529-545.
31. Mackenzie IR, Feldman HH. Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. J Neuropathol Exp Neurol 2005; 64:730-739.
32. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314:130-133.
33. Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Gen 2010; 19:R46-R64.
34. Buratti E, Baralle FE. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci 2008;13: 867-878.
35. Giordana MT, Piccinini M, Grifoni S, et al. TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol. 2010; 20:351-360.
36. Ou SH, Wu F, Harrich D, Garcia-Martinez LF and Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 1995; 69:3584-3596.
37. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323:1205-1208.
38. Doi H, Okamura K, Bauer PO, et al. RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells. J Biol Chem 2008; 283:6489-6500.
39. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004;27:723-749.
40. Cleveland DW, Sullivan KF. Molecular biology and genetics of tubulin. Annu Rev Biochem 1985; 54:331-65.
41. El-Kadi AM, Soura V, Hafezparast M. Defective axonal transport in motor neuron disease. J Neurosci Res 2007; 85:2557-2566.
42. Hirokawa N, Takemura R. Molecular motors in neuronal development, intracellular transport and diseases. Curr Opin Neurobiol 2004; 14:564-73.
43. Reid, E., Kloos M., Ashley-Koch A. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet 2001; 71:1189-1194.
44. Puls I, Oh SJ, Sumner CJ, et al. Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann. Neurol 2005; 57:687-694.
45. Laird FM: Neuronal expression of an ALS-associated mutation dynactin P150 glued in mice causes motor neuron disease. Amyotroph. Lateral Scler Other Motor Neuron Disord 2005; 6:22-23.
46. LaMonte BH, Wallace KE, Holloway BA, et al. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002; 34:715-727.
47. Hafezparast M, Ahmad-Annuar A, Hummerich H, et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 2003; 300:808-812.
48. Dupuis L, Fergani A, Braunstein KE, et al. Mice with a mutation in the dynein heavy chain 1 gene display sensory neuropathy but lack motor neuron disease. Exp Neurol 2009; 215:146-152.
49. Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 1999; 2:50-56.
50. Miller DW, Cookson MR, Dickson DW. Glial cell inclusions and the pathogenesis of neurodegenerative diseases. Neuron Glia Biol 2004; 1:13-21.
51. Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003; 302:113-117.
52. Boillee S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006; 312:1389-1392.
53. Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007; 10:615-622.
54. Thonhoff JR, Ojeda L, Wu P. Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis. Curr Stem Cell Res Ther 2009; 4:178-199.
55. Zhao W, Xie W, Le W, et al. Activated microglia initiate motor neuron injury by a nitric oxide and glutamatemediated mechanism. J Neuropathol Exp Neurol 2004; 63:964-977.
56. Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet 2004; 75:933-947
57. Zhao W, Xie W, Xiao Q, et al. Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J Neurochem 2006; 99:1176-87.
58. Guégan C, Przedborski S. Programmed cell death in amyotrophic lateral sclerosis. J Clin Invest 2003; 111:153-161.
59. Sathasivam S, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis-what is the evidence? Lancet Neurol 2005; 4:500-509.
60. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999; 58:459-471.
61. Graeber MB, Moran LB. Mechanisms of cell death in neurodegenerative diseases: fashion, fiction and facts. Brain Pathol 2002; 12:385-390.